Stalking Ebola

While the spotlight has moved away from Ebola, companies and academics are still pushing to understand more about the virus and make new therapeutics, in anticipation of the next outbreak. For scientists, the legacy of the last one is more than increased funding, as antibodies from survivors are providing key clues about how to target the principal antigen for maximum effect.

Last month, two groups published studies in Science that described new structural insights about the antigen, Ebolavirus glycoprotein, and identified several new antibodies against it, at least one of which could enter the clinic before year end...